HC Wainwright Forecasts Lower Earnings for Plus Therapeutics

Plus Therapeutics, Inc. (NASDAQ:PSTV) – Research analysts at HC Wainwright decreased their Q1 2026 EPS estimates for Plus Therapeutics in a research report issued on Monday, March 16th. HC Wainwright analyst S. Lee now expects that the company will earn ($0.04) per share for the quarter, down from their previous estimate of ($0.03). HC Wainwright has a “Buy” rating and a $1.00 price objective on the stock. The consensus estimate for Plus Therapeutics’ current full-year earnings is ($2.30) per share. HC Wainwright also issued estimates for Plus Therapeutics’ Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.15) EPS, FY2027 earnings at ($0.10) EPS, FY2028 earnings at ($0.01) EPS and FY2029 earnings at $0.12 EPS.

PSTV has been the subject of a number of other reports. Lake Street Capital began coverage on Plus Therapeutics in a report on Tuesday, February 3rd. They set a “buy” rating and a $2.00 price target for the company. Ascendiant Capital Markets decreased their target price on Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating on the stock in a report on Friday, November 21st. D. Boral Capital restated a “buy” rating and issued a $3.00 target price on shares of Plus Therapeutics in a research note on Thursday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Plus Therapeutics in a report on Thursday, January 22nd. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $5.60.

Plus Therapeutics Price Performance

Shares of PSTV opened at $0.24 on Wednesday. The company has a market capitalization of $41.36 million, a P/E ratio of -0.19 and a beta of 0.79. Plus Therapeutics has a one year low of $0.16 and a one year high of $2.08. The business’s 50 day simple moving average is $0.29 and its 200-day simple moving average is $0.47.

Institutional Trading of Plus Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC acquired a new position in shares of Plus Therapeutics in the 2nd quarter valued at $41,000. Altium Capital Management LLC acquired a new stake in shares of Plus Therapeutics during the third quarter worth $628,000. Scientech Research LLC bought a new stake in Plus Therapeutics in the third quarter valued at about $100,000. Susquehanna International Group LLP acquired a new stake in shares of Plus Therapeutics in the 3rd quarter valued at approximately $46,000. Finally, Geode Capital Management LLC raised its holdings in Plus Therapeutics by 72.5% in the fourth quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock worth $719,000 after purchasing an additional 589,544 shares during the period. Institutional investors own 3.28% of the company’s stock.

Plus Therapeutics News Summary

Here are the key news stories impacting Plus Therapeutics this week:

• Positive Sentiment: D. Boral Capital reaffirmed a “buy” rating and set a $3.00 price target (very large upside vs. recent levels), a loud bullish signal that can attract speculative buying and broader investor interest. Benzinga
• Positive Sentiment: Plus published a health-economics analysis presented at ISPOR showing CNSide may reduce healthcare costs for leptomeningeal metastases by ~40% and emphasized value of earlier diagnosis as it enters U.S. commercialization — a commercial/economic data point that could support pricing, payer conversations and launch uptake. GlobeNewswire: CNSide ISPOR Analysis
• Neutral Sentiment: The company is scheduled to release quarterly earnings this week — a routine catalyst that could drive volatility depending on guidance and cash-burn metrics. Plus Therapeutics to Release Quarterly Earnings
• Neutral Sentiment: Broker coverage updates and long-horizon forecasts (FY2030) were published, which may shape investor expectations but are distant and model-dependent. Brokers Issue Forecasts for PSTV FY2030 Earnings
• Negative Sentiment: HC Wainwright trimmed near-term quarterly EPS estimates (several Q1–Q4 2026 cuts to ~$-0.04) while keeping a Buy rating and a $1.00 target — the downward near-term revisions highlight persistent losses and raise the importance of upcoming commercial execution and cash management. MarketBeat: HC Wainwright Notes

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.